Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026GlobeNewsWire • 10/23/26
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceGlobeNewsWire • 09/14/26
Pasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesGlobeNewsWire • 09/03/26
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 07/21/26
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitGlobeNewsWire • 07/08/26
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionGlobeNewsWire • 06/30/26
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialGlobeNewsWire • 06/16/26
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF ConferenceGlobeNewsWire • 06/15/26
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 06/10/26
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)GlobeNewsWire • 06/02/26
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerGlobeNewsWire • 05/04/26
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityGlobeNewsWire • 04/01/26
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptSeeking Alpha • 02/27/26
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/17/26
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesGlobeNewsWire • 01/13/26
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockGlobeNewsWire • 12/02/25
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common StockGlobeNewsWire • 11/28/25
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataGlobeNewsWire • 11/24/25
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsGlobeNewsWire • 11/21/25
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer StudyGlobeNewsWire • 11/20/25
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsGlobeNewsWire • 11/04/25
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsGlobeNewsWire • 09/16/25
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 08/29/25
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsGlobeNewsWire • 07/31/25